Chromosomal Instability and Phosphoinositide Pathway Gene Signatures in Glioblastoma Multiforme by unknown
Chromosomal Instability and Phosphoinositide Pathway Gene
Signatures in Glioblastoma Multiforme
Mark G. Waugh
Received: 18 August 2014 /Accepted: 30 November 2014 /Published online: 15 December 2014
# The Author(s) 2014. This article is published with open access at Springerlink.com
Abstract Structural rearrangements of chromosome 10 are
frequently observed in glioblastoma multiforme and over
80 % of tumour samples archived in the catalogue of somatic
mutations in cancer database had gene copy number loss for
PI4K2A which encodes phosphatidylinositol 4-kinase type
IIalpha.PI4K2A loss of heterozygositymirrored that ofPTEN,
another enzyme that regulates phosphoinositide levels and
also PIK3AP1,MINPP1, INPP5A and INPP5F. These results
indicated a reduction in copy number for a set of
phosphoinositide signalling genes that co-localise to chromo-
some 10q. This analysis was extended to a panel of
phosphoinositide pathway genes on other chromosomes and
revealed a number of previously unreported associations with
glioblastoma multiforme. Of particular note were highly pen-
etrant copy number losses for a group of X-linked
phosphoinositide phosphatase genes OCRL, MTM1 and
MTMR8; copy number amplifications for the chromosome
19 genes PIP5K1C, AKT2 and PIK3R2, and also for the
phospholipase C genes PLCB1, PLCB4 and PLCG1 on chro-
mosome 20. These mutations are likely to affect signalling
and trafficking functions dependent on the PI(4,5)P2,
PI(3,4,5)P3 and PI(3,5)P2 lipids as well as the inositol phos-
phates IP3, IP5 and IP6. Analysis of flanking genes with
functionally unrelated products indicated that chromosomal
instability as opposed to a phosphoinositide-specific process
underlay this pattern of copy number variation. This in silico
study suggests that in glioblastoma multiforme, karyotypic
changes have the potential to cause multiple abnormalities in
sets of genes involved in phosphoinositide metabolism and
this may be important for understanding drug resistance and
phosphoinositide pathway redundancy in the advanced dis-
ease state.








Glioblastomamultiforme is themost commonmalignant brain
tumour and accounts for the majority of deaths from this
disease. A number of comprehensive recent publications have
described the genetic changes associated with glioblastoma
multiforme [1–13]. However, rather than assessing global
genomic changes, this study concerns mutations likely to
affect phosphoinositide metabolism and signalling. The initial
focus herein is on phosphatidylinositol (PI) 4-kinase type IIα
(PI4K2A), a 55 kDa constitutively membrane-associated en-
zyme which localises mainly to the trans-Golgi network
(TGN) and late endosomes where it catalyses the formation
of PI4P by D4 phosphorylation of its substrate lipid phos-
phatidylinositol [14]. PI4K2A is unique amongst the
phosphoinositide kinases in that it is regulated by dual
palmitoylation within its catalytic domain and by its targeting
to cholesterol-rich membrane rafts where its activity is very
sensitive to alterations to membrane sterol levels [15–22]. A
number of intracellular trafficking roles have been described
for this enzyme including the recruitment of the clathrin
adapters AP-1 [23] and GGA [24] to TGN membranes and
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AP-3 to late endosomes [25]. More recent work has
revealed the enzyme’s function in regulating Wnt recep-
tor signalling [26, 27] and described its reciprocal reg-
ulation on endosomal membranes by the ubiquitin ligase
itch [28]. In the central nervous system, PI4K2A is by
far the most prevalent PI kinase activity and is most
strongly expressed in cerebellar Purkinje cells and as-
trocytes [29]. Astrocytomas and subsequently glioblas-
toma multiforme usually develop from astrocytes, and
this prompted us to investigate whether PI4K2A muta-
tions are associated with this disease.
Several studies have demonstrated that PI4K2A controls
the signalling and trafficking of cell surface receptors such as
EGFR [30–32] and HER2 [33] which are known to stimulate
oncogenic signalling. EGFR is often overexpressed in glio-
blastoma [12] and anti-EGFR therapies are a potential targeted
therapy in this difficult-to-treat disease [4, 13, 34–40]. In
addition to EGFR overexpression, loss of the tumour suppres-
sor PTEN is a common feature in glioblastoma [1, 41–43].
PTEN is a phosphoinositide 5-phosphatase that in normal
cells rapidly dephosphorylatesthe PI3K lipid product
PI(3,4,5)P3 which is a potent stimulator of signalling via the
Akt/mTOR pathway [44–47]. Deletion of PTEN results in
sustained and elevated PI3K signalling and augmented cell
proliferation [48]. Given that PI4KIIα has roles in regulating
both EGFR and AKT signalling, an initial aim of this study
was to ascertain if the PI4K2A gene is mutated in glioblasto-
ma. Through analysis of publically accessible genomic data
available via the COSMIC resource, we were able to establish
that point mutations of PI4K2Awere rare in glioblastoma but
more than 80% of samples from a cohort of 638 exhibited loss
of PI4K2A heterozygosity; this level of copy number variation




The Catalogue of Somatic Mutations In Cancer (COSMIC)
bioinformatics resource (http://www.sanger.ac.uk/cosmic)
[49, 50] established and maintained by the Wellcome Trust
Sanger Institute was used in order to identify mutations in the
638 individual tumour samples analysed by the Cancer
Genome Atlas (TCGA). For these samples in the COSMIC
database, gene copy number analysis was carried out using
ASCAT (Allele-Specific Copy number Analysis of Tumours)
algorithm software [51] available at http://heim.ifi.uio.no/
bioinf/Projects/ASCAT. For this analysis, the average copy
number for the genome is 1.90 and a reduction in total copy
number to a value of 1.30 or less demarcates a loss, while
a gain was set at copy number ≥ 3.
Protein Expression Analysis
The Human Protein Atlas [52, 53] (www.proteinatlas.org)
online resource was utilised to investigate the expression of
candidate proteins identified from the genomic analyses in
immunohistochemically stained control cerebral cortex tissue
and glioblastoma patient samples. The immunohistochemical
data included here derives only from antibodies that also
detected the correct size protein band on Western blots.
String Analysis
The String [54] Search Tool for the Retrieval of Interacting
Genes/Proteins software (http://string-db.org) was used to
visualise interactions and networks amongst the protein
products from the phosphoinositide pathway genes identified
as having the highest levels of copy number variation in
glioblastoma.
Results and Discussion
As a first step, we sought to determine if there was any
evidence for PI 4-kinase mutations in glioblastoma. We used
the COSMIC resource and genomic data from 638 different
glioblastoma patient samples to investigate the mutational
status of the 4 human PI 4-kinase genes, PI4KA, PI4KB,
PI4K2A and PI4K2B. Point mutations giving rise to amino
acid changes were rare for all four PI 4-kinase genes and were
observed in less than 1 % of all the samples in the combined
patient cohort. However, analysis of gene copy number vari-
ation revealed that in 82 % of cases, there was a decrease in
PI4K2A copy number and this was not seen for any of the
other PI 4-kinase genes (Fig. 1). The pattern of PI4K2A copy
number variation was also compared with a panel of
established oncogenes and tumour suppressors composed of
PTEN, EGFR, HER2 and KRAS (Fig. 1). From this initial
comparison, it became apparent that the level of PI4K2A gene
copy number loss in glioblastoma mirrored that of a tumour
suppressor such as PTEN as opposed to an oncogene such as
EGFR that had an increased copy number. The loss of
heterozgosity for PTEN and PI4K2A is biologically signifi-
cant as these genes both localise to chromosome 10q and
suggests that their copy number variation was due to a chro-
mosome 10q deletion. For this to be the case, then the nearest
neighbour genes to PI4K2A should also undergo a similar
degree of gene copy number loss. To investigate this possibil-
ity, two genes immediately upstream and downstream of
PI4K2A were identified. The upstream genes at the 10q24.2
locus were HOGA1 and MORN4 while the immediate down-
stream genes were AVPI1 andMARVELD1. Consistent with a
copy number change caused by chromosomal loss, the pattern
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of copy number variation (0.2 % gain and 82 % loss) for each
of these flanking genes in glioblastomawas almost identical to
PI4K2A and PTEN. However, unlike PTEN and PI4K2A,
there is no evidence for any of these flanking gene products
being involved in receptor stimulated oncogenic signalling.
These results also demonstrate that the copy number reduction
of genes localised to chromosome 10 was not specific to the
phosphoinositide pathway and that these changes could be
explained by an overall loss of chromosome 10
heterozygosity.
For a more complete analysis of genomic changes across
the entire phosphoinositide pathway, a panel of genes
encoding proteins involved in phosphoinositide metabolism,
signalling and trafficking was investigated. Forty-five addi-
tional genes encoding phosphoinositide kinases, phosphatases,
phospholipase C isozymes and also effector proteins such as
the three Akt isoforms were included in this expanded analy-
sis. Amongst the glioblastoma samples on COSMIC, copy
number variation was frequently observed in this group of
genes (Table 1). Copy number loss was most pronounced for
phosphoinositide pathway genes localised to both arms of
chromosome 10 and the X chromosome. For copy number
amplifications, the greatest increases were seen for genes on
chromosomes 19 and 20 followed by chromosomes 3 and 1.
This rank ordering of chromosomes is in line with their known
susceptibilities to undergo deletion or amplification in glio-
blastoma [42, 55–57]. Significantly, using this approach, it was
possible to identify 17 new gene mutations, present in at least
10 % of the glioblastoma multiforme patient samples, with the
potential to affect phosphoinositidemetabolism and signalling.
These results revealed that chromosomal instability affected
particular sets of genes with the potential for chromosome-
specific effects on phosphoinositide lipid levels metabolism
(Table 1) with dyshomeostasis of PI(3,4,5)P3, PI(4,5)P2 and
PI(3,5)P2 the most likely outcomes in glioblastoma
multiforme. In the case of chromosome 10q loss, in addition
to PI4K2A and PTEN, copy number losses in over 80 % of
tumour samples were ident i f ied for four o ther
phosphoinositide pathway genes. The effected genes were
PIK3AP1 (10q24.1) also known as B-cell adaptor for phos-
phatidylinositol 3-kinase (BCAP), MINPP1 (10q23), INPP5F
(10q26.11) and INPP5A (10q26.3). Two of these gene prod-
ucts, PTEN and INPP5F, are phosphoinositide 5-phosphatases
and reductions in their enzymatic activities have the potential
to induce sustained PI(3,4,5)P3 stimulation of the PI3K/mTOR
pathway. However, unlike PTEN, INPP5F has not previously
been considered as an oncogene in glioblastoma multiforme.
Nevertheless, the potential decrease of PI3K lipid substrate
brought about by the combination of PI4K2A loss and reduced
PI3K activation due to diminished levels of the stimulatory
Fig. 1 a Gene copy number
variation for the four human PI 4-
kinase isozymes in glioblastoma
multiforme. b Comparison of
gene copy number variation for
PI4K2Awith established
oncogenes. Data was derived
from mining the COSMIC
database
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Table 1 A summary of the copy number changes in glioblastoma multiforme for a panel of genes involved in phosphoinositide signalling and
trafficking
Gene Chromosome Gain Loss Main effect on lipids Previous report in glioma
INPP5B (1p34) 1 8.80 2.70 PI(4,5)P2 ↓ No
PIK3R3 (1p36.2) 1 8.80 2.20 PI(3,4,5)P3 ↑ Yes [88]
PI4KB (1q21) 1 11.30 0.60 PI4P ↑ No
PIP5K1A (1q21.3) 1 11.30 0.60 PI(4,5)P2 ↑ No
AKT3 (1q44) 1 12.20 2.00 – Yes [89]
PIK3C2B (1q32) 1 19.80 0.60 PI(3,4)P2 ↑ Yes [45, 90, 91]
INPP1 (2q32) 2 2.50 3.80 IP2 ↑ No
INPP4A (2q11.2) 2 4.50 1.60 PI3P ↑ No
PIKFYVE (2q34) 2 3.50 2.40 PI5P/PI(3,5)P2 ↑ No
SACM1L (3p21.3) 3 5.80 7.80 PI4P ↑ No
PIK3R4 (3q22.1) 3 7.00 6.00 PI3P ↑ No
PIK3CB (3q22.3) 3 6.90 5.20 PI(3,4,5)P3 ↑ Yes [92]
PIK3CA (3q26.3) 3 11.80 3.50 PI(3,4,5)P3 ↑ Yes [93]
INPP4B (4q31.21) 4 3.60 5.80 PI(3,4)P2 ↑ No
PIK3R1 (5q13.1) 5 4.40 6.60 PI(3,4,5)P3 ↓ Yes [94]
FIG 4 (6q21) 6 1.60 18.80 PI(3,5)P2 ↑ No
MTMR7 (8p22) 8 6.30 8.00 PI3P ↑ No
PIP4K2A (10p12.2) 10 2.20 77.60 PI(4,5)P2 ↓ No
MINPP1 (10q23) 10 0.30 83.90 IP6 ↑ No
PTEN (10q23.3) 10 2.00 84.80 PI(3,4,5)P3 ↑ Yes
PIK3AP1 (10q24.1) 10 0.30 83.40 PI(3,4,5)P3 ↓ No
INPP5F (10q26.11) 10 84.30 PI(3,4,5)P3 ↑ No
INPP5A (10q26.3) 10 83.40 IP3 ↑ Yes [66]
PIK3C2A (11p15.5-p14) 11 2.50 12.10 PI3P/PI(3,4)P2 ↓ No
PLCB3 (11q13) 11 1.60 11.30 PI(4,5)P2 ↑ No
MTMR2 (11q22) 11 2.70 9.70 PI3P ↑ No
PIK3C2G (12p.12) 12 8.90 9.90 PI(3,4,5)P3 ↑ or ↓ Yes [95]
MTMR6 (13q12) 13 1.60 26.50 PI3P/PI(3,5)P2 ↑ No
AKT1 (14q32.32) 14 4.50 23.00 – Yes
PLCB2 (15q15) 15 1.10 21.90 PI(4,5)P2 ↑ No
PLCG2 (16q24.1) 16 3.10 11.60 PI(4,5)P2 ↑ No
PIK3R5 (17p13.1) 17 2.70 10.70 PI(3,4,5)P2 ↑ No
PIP4K2B (17q12) 17 2.80 10.70 PI(4,5)P2 ↓ No
MTMR4 (17q22–q23) 17 6.40 5.50 PI3P ↑ No
PIK3C3 (18q12.3) 19 4.90 7.50 PI3P ↓ No
PIP5K1C (19p13.3) 19 30.20 5.00 PI(4,5)P2 ↑ No
PIP5K1B (19; 19 C1) 19 8.00 9.70 PI(4,5)P2 ↑ No
AKT2 (19q13.1–q13.2) 19 25.60 5.80 – Yes [89, 96]
PIK3R2 (19q13.2–q13.4) 19 30.60 3.30 PI(3,4,5)P3 ↑ No
PLCB4 (20p12) 20 31.80 2.40 PI(4,5)P2 ↓ No
PLCB1 (20p12) 20 34.60 2.20 PI(4,5)P2 ↓ No
PLCG1 (20q12–q13.1) 20 30.30 2.20 PI(4,5)P2 ↓ Yes[97]
PIK3IP1 (22q12.2) 22 1.90 27.90 PI(3,4,5)P3 ↑ Yes [98]
MTMR8 (Xq11.2) X 5.60 65.70 PI3P/PI(3,5)P2 ↑ No
OCRL (Xq25) X 4.50 66.60 PI(4,5)P2 ↑ No
MTM1 (Xq28) X 4.50 66.00 PI3P/PI(3,5)P2 ↑ No
The chromosomal localisation of each gene appears in brackets after its name. The “main effect on lipid” column refers to the predicted effect on either
phosphoinositide lipid or inositol phosphate levels depending on whether gene copy number loss or gain predominates. The “previously reported in
glioma” column indicates where there has been a previous publication demonstrating that a gene or gene product is involved in glioblastomamultiforme.
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protein PIK3AP1, could potentially off-set the effects of re-
duced PI(3,4,5)P3 degradation. Although this latter scenario is
more speculative since there is no evidence yet for PI4K2A
positively affecting PI(3,4,5)P3 generation [31] or for
PIK3AP1 stimulating PI3K activity in the brain, even though
this protein is a negative regulator of PI3K signalling and a
potential tumour suppressor of cancers affecting other tissues
[58–63].
Gene copy numbers for MINPP1 and INPP5A, two en-
zymes involved in the dephosphorylation of soluble inositol
phosphates, were also reduced in the majority of glioblastoma
multiforme patient samples. INPP5A [64–68] dephosphory-
lates the 5-position of the receptor-activated PLC product
inositol (1,4,5)-tris-phosphate (IP3) which binds intracellular
IP3 receptors to release Ca
2+ stored in endoplasmic reticulum
stores, while MINPP1 [69–72] is a 3-phosphatase that can
hydrolyze multiple soluble inositol phosphate substrates
including the downstream IP3 products inosi tol
pentakisphosphate (IP5) and inositol hexakisphosphate (IP6).
There is some evidence that IP6 can function asa possible
alternative chemical energy supply to ATP with the potential
to drive tumour growth under anaerobic conditions [71, 72].
In this way, loss of both chromosome 10 encoded inositol
phosphatases has the potential to induce sustained and aug-
mented signalling by receptors that activate phospholipase C.






Cerebral Cortex GlioblastomaFig. 2 Expression of
phosphoinositide pathway
proteins in healthy cerebral cortex
tissue and glioblastoma





directed against the protein
products of PI4K2A, PTEN,
INPP5A, MINPP1 and AKT2.
Antibody binding appears as
brown/black staining on a
background of blue haematoxylin
counterstain. All images are from
the Human Protein Atlas
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tumour suppressor PTEN and two reports mentioning
INPP5A [64, 66], none of the other phosphoinositide pathway
genes on chromosome 10 discussed here has hitherto been
associated with glioblastoma multiforme.
Another genomic alteration of note identified here that
affected 65 % of the glioblastoma multiforme patient samples
was copy number loss for a set of three phosphoinositide
phosphatase genes associated with the X chromosome. These
genes were MTMR8 (Xq11.2), OCRL (Xq25) and MTM1
(Xq28), and once again none of these phosphoinositide genes
has previously been associated with glioblastoma multiforme
(Table 1). Loss-of-function mutations in the protein products
of each of these genes are known to cause different X-linked
neurological diseases [73, 74] and endosomal trafficking
Fig. 3 a STRING analysis
illustrating the protein interaction
network for the phosphoinositide
pathway enzymes most
commonly affected by gene copy
number variation in glioblastoma
multiforme. b Diagram
illustrating how the protein
interaction network would reset
following a chromosome 10
deletion
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defects that feature accumulations of their respective substrate
lipids; PI3P and PI(3,5)P2 in the case of MTM1 [75–77] and
MTMR8 [78], and PI(4,5)P2 for OCRL [79]. This trio of
phosphatase genes has not been previously linked to cancer
but in light of their proposed functions in endosomal traffick-
ing [80–82] and autophagy [78, 83, 84], it is possible that loss
of this gene combination results in profound defects in the
intracellular trafficking and degradation of receptor tyrosine
kinases [75] and, consequently, augmented pro-tumourigenic
and proliferative signalling.
A number of potential gain-of-function mutations due to
chromosomal amplifications were also identified in the patient
tumour samples and these included several phosphoinositide
pathway genes never before linked to cancers affecting the
central nervous system (Table 1). The main loci that exhibited
copy number gain were chromosomes 20 and 19 in approxi-
mately 30 % of the glioblastoma samples, and chromosome 1
in around 10 % of the patient cohort. Interestingly, while
chromosomal loss impacted heavily on phosphoinositide
phosphatases, thereby potentially augmenting signalling out-
puts, gene copy number changes associated with chromosom-
al amplification were also found to be biased towards poten-
tiating oncogenic signalling (Table 1). However, for gene
amplifications, the main changes were not in phosphoinositide
phosphatase genes but more so in genes encoding
phosphoinositide kinases such as PIP5K1C (19p13.3) and
PIK3C2B (1q32), second messenger-generating enzymes
such as the PLC isozymes PLCB4 (20p12), PLCB1 (20p12)
and PLCG1 (20q12-q13.1) and phosphoinositide-dependent
signalling proteins such as AKT2 (19q13.1-q13.2). These
findings imply that chromosomal numerical aberrations that
result in either gain or loss of gene copy number in glioblas-
toma multiforme can result in pro-oncogenic signalling and
trafficking defects via the phosphoinositide pathway. This
raises the possibility these altered phosphoinositide signal-
ling outputs could be selected for on the basis that they
confer a survival advantage during tumour progression. Fur-
ther functional studies are required to investigate this
hypothesis.
The Human Protein Atlas archive of immunohistochemically
stained cancer tissues was interrogated to uncover if the gene
copy number variation in the phosphoinositide pathway was
reflected in altered protein expression (Fig. 2). For comparison
purposes, immunohistochemically stained normal cerebral cortex
tissue was included in the analyses. However, the cytological
composition of the cerebral cortex differs greatly from that found
in glioblastoma tumour samples, with the former containing a
high density of neurons whereas the latter is composed almost
entirely of tumour cells derived from astrocytes. Thus, given
these underlying histological differences, it is difficult to directly
compare patterns of expressed proteins between control and
patient samples. Notwithstanding these caveats, it was possible
to identify high-grade glioblastoma samples that exhibited
patterns of protein expression that were consistent with the gene
copy number variation results. More specifically, high levels of
gene copy number loss were found for PTEN, PI4K2A, INPP5F
and MINPP1 and there was concomitant reduced or absent
exp re s s ion o f the i r cogna t e gene p roduc t s in
immunohistochemically stained glioblastoma tissues (Fig. 2).
PI4K2A protein expression was not detected in 6/11 tumour
samples; PTEN, was not detected in 10/12; INPP5A exhibited
low to moderate staining in 3/12 diseased tissues and MINPP1
was not detected in 8/10 tumours. Conversely, for AKT2 which
was subject to a copy number increase, the corresponding protein
products were intensely stained in high-grade glioblastoma sam-
ples. These images are included to provide some evidence that
the protein expression patterns predicted by the genomic analysis
could be observed in an independent immunohistochemical
study. It is very important to note that these results derive from
malignancies where the karyotype has not been characterised.
Therefore it is not possible to conclude thatthe observed
protein expression patterns are a consequence of chromosomal
numerical abnormalities and associated changes in gene copy
number. Proof of such a functional association is beyond the
scope of the current in silico study, and future studies will aim to
simultaneously investigate the link between glioblastoma
karyotype, gene copy number status and the expression levels
of enzymes involved in phosphoinositide signalling and
trafficking.
The functional relationships between the most commonly
affected phosphoinositide pathway gene products, defined as
copy number variation in ≥30 % of samples, were assessed
using freely available STRING software (Fig. 3). Using this
approach it was established that all of the identified gene
products are highly connected at the protein interaction level.
Hence, a deletion or amplification of any one element in this
putative pathway has the potential to reset the entire tumour-
specific network of phosphoinositide-metabolising enzymes.
To illustrate this scenario, STRING analysis is also shown for
a tumour cell with a homozygous chromosome 10p deletion in
order to show how the phosphoinositide metabolic network in
glioblastoma could reorganise when a subset of gene products
are lost through a gross karyotypic change. Themajority of the
affected gene products identified are involved in lipid dephos-
phorylation and hydrolysis, indicating that in glioblastoma,
changes to phosphoinositide metabolism occur mainly via
defective catabolism as opposed to altered synthesis. Howev-
er, the degree to which the balance between synthesis and
degradation is deregulated depends very much on the pattern
of chromosomal instability in each tumour, thus leading to
different permutations of phosphoinositide signalling and traf-
ficking outputs contingent on which subset of genes is affect-
ed. These findings have implications for our understanding of
drug resistance and target selection, particularly when it
comes to chemotherapeutics aimed at inhibiting the
PI3K/AKT/mTOR pathway [85–87]. Rather than focusing
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on a single enzyme, a more productive approach in cancer
therapeutics could be to map the overall landscape of
phosphoinositide pathway mutations present and to consider
how these relate to the chromosomal structural abnormalities
prevalent in aggressive cancers such as glioblastoma
multiforme. This strategy will enable the identification of
functionally redundant and alternative biochemical pathways
to drug resistance that result from gene copy number variation
and tumour-specific chromosomal aberrations.
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